PuriBlood Medical Co (ROCO:6847) Change In Receivables: NT$-27.30 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6847 PuriBlood Medical Co Ltd ROCO:6847
72 GF Score
Price NT$70.30
GF Value NT$63.44
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is PuriBlood Medical Co Change In Receivables?

PuriBlood Medical Co ROCO:6847 -1.40% 72 Change In Receivables is NT$-27.30 Mil as of Jun. 2026. GuruFocus rates ROCO:6847 with a GF Score™ of 72/100 and a GF Value™ of NT$63.44 (Modestly Overvalued). The stock has 7 warning signs investors should review.

PuriBlood Medical Co's change in receivables for the quarter that ended in Jun. 2026 was NT$0.16 Mil. It means PuriBlood Medical Co's Accounts Receivable declined by NT$0.16 Mil from Dec. 2025 to Jun. 2026 .

PuriBlood Medical Co's change in receivables for the fiscal year that ended in Dec. 2025 was NT$-15.74 Mil. It means PuriBlood Medical Co's Accounts Receivable increased by NT$15.74 Mil from Dec. 2024 to Dec. 2025 .

PuriBlood Medical Co's Accounts Receivable for the quarter that ended in Jun. 2026 was NT$29.93 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. PuriBlood Medical Co's Days Sales Outstanding for the six months ended in Jun. 2026 was 142.03.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. PuriBlood Medical Co's liquidation value for the six months ended in Jun. 2026 was NT$-19.42 Mil.

PuriBlood Medical Co  (ROCO:6847) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

PuriBlood Medical Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=29.928/38.457*91
=142.03

2. In Ben Graham's calculation of liquidation value, PuriBlood Medical Co's accounts receivable are only considered to be worth 75% of book value:

PuriBlood Medical Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=39.778-95.194+0.75 * 29.928+0.5 * 27.107
=-19.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PuriBlood Medical Co Change In Receivables Related Terms

PuriBlood Medical Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for PuriBlood Medical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PuriBlood Medical Co Change In Receivables Chart

PuriBlood Medical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.50 -10.37 10.15 -6.32 -15.74

PuriBlood Medical Co Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.51 -11.83 11.73 -27.47 0.16
ROCO:6847
72GF Score
PuriBlood Medical Co Ltd ROCO:6847
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PuriBlood Medical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-27.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of NT$-27.30 Mil mean?
PuriBlood Medical Co (ROCO:6847) has a Change In Receivables of NT$-27.30 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PuriBlood Medical Co and its competitors.
Is PuriBlood Medical Co's Change In Receivables too high?
PuriBlood Medical Co's current Change In Receivables is NT$-27.30 Mil. Overall, PuriBlood Medical Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PuriBlood Medical Co's Change In Receivables compare to TMO and DHR?
PuriBlood Medical Co's Change In Receivables of NT$-27.30 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Diagnostics & Research company?
A good Change In Receivables depends on the Medical Diagnostics & Research industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for PuriBlood Medical Co and its competitors. PuriBlood Medical Co's current Change In Receivables is NT$-27.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuriBlood Medical Co stock overvalued right now?
Based on GuruFocus' analysis, PuriBlood Medical Co (ROCO:6847) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$63.44, compared to a current price of NT$70.30 — trading 10.8% above its estimated fair value. The current Change In Receivables is NT$-27.30 Mil. PuriBlood Medical Co's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For PuriBlood Medical Co (ROCO:6847), the current Change In Receivables is NT$-27.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PuriBlood Medical Co (ROCO:6847) Overvalued in 2026?

Based on GuruFocus' analysis, PuriBlood Medical Co stock appears to be overvalued. The current stock price of NT$70.30 is trading 10.8% above its estimated GF Value™ of NT$63.44. GuruFocus considers PuriBlood Medical Co to be Modestly Overvalued.

Key valuation signals for ROCO:6847:

  • Change In Receivables: NT$-27.30 Mil
  • GF Value™: NT$63.44 vs. price of NT$70.30 (10.8% above fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6847 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PuriBlood Medical Co Business Description

Address Gongye E. 9th Road, Baoshan Township, 2nd Floor, No.11, Hsinchu County, Baoshan, TWN
PuriBlood Medical Co Ltd is engaged in developing solutions for leukoreduction, cell separation, and anti-fouling materials. Its technology protects to supports living beings from medical devices to daily protection. The products of the company include Leukoreduction, Cell Separation, and P-tex.
72GF Score

Get the complete analysis for ROCO:6847

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.30
Price
NT$63.44
GF Value